ABOUT IMMUSAFE
ImmuSAFE™ is a novel, lab-based biochip test for COVID-19 that enables highly quantitative determination of both level and target locations of SARS-CoV-2 antibodies in an individual.
The test will be able to:
Scenario 1- suspected COVID-19 positive individual
- Confirm with high accuracy if an individual has been infected with the SARS-CoV-2 virus.
- Determine whether the level and target locations of the antibodies in an individual are likely to offer protection against COVID-19 infection.
Scenario 2- following COVID-19 vaccination
- Confirm that an individual has generated a sufficiently strong immune response against the SARS-CoV-2 virus.
- Confirm the status of ongoing protection and determine whether a booster vaccine is required.
SARS-CoV-2 Virus
Accurate determination of the antibody levels produced at different stages following an infection is key to understanding the level and prevalence of neutralizing antibodies.
ImmuSAFE® has identified 6 different functional domains of the Nucleocapsid protein, and 3 different functional domains of the Spike protein.
What are protective antibodies?
Protective antibodies (or neutralizing antibodies) defend your body from viruses and stops the spread of the virus. It is produced as part of your immune response from being infected or vaccinated.
ImmuSAFE™ has an accuracy of 100% as validated by IMR
- The Institute of Medical Research (IMR) is an agency under the Ministry of Health (MoH) Malaysia.
- ImmuSAFE™ can identify and measure the presence of neutralizing antibodies with high accuracy and is able to quantify the levels of antibodies.
- ImmuSAFE™ can also determine which epitopes the neutralizing antibodies bind to.
